Jinan Liu, Sudheer Matangi, Yogitha Malempati, Adnan Nasir, David Rosmarin
{"title":"成人白癜风患者自身免疫性合并症的患病率和相关性：美国研究的系统文献综述和荟萃分析","authors":"Jinan Liu, Sudheer Matangi, Yogitha Malempati, Adnan Nasir, David Rosmarin","doi":"10.1007/s13555-025-01506-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Vitiligo is an autoimmune, depigmenting skin disease affecting 0.1-1.6% of adults in the USA. Despite observed correlations between vitiligo and other autoimmune conditions in global patient populations, a focused review of comorbidities in US patients with vitiligo is lacking. This systematic literature review and meta-analysis evaluated the prevalence of autoimmune comorbidities in adult patients with vitiligo in the USA.</p><p><strong>Methods: </strong>A systematic literature search of the PubMed and Embase electronic databases (January 1, 2012-November 30, 2022) selected observational studies reporting data on prevalence of autoimmune diseases in US patients with vitiligo. The Grading of Recommendations, Assessment, Development, and Evaluation approach for prognosis was applied to assess certainty of evidence.</p><p><strong>Results: </strong>Eight studies were eligible for inclusion, encompassing 10,246 patients with vitiligo. Thyroid diseases (14.2%), psoriasis (5.1%), rheumatoid arthritis (3.2%), and alopecia areata (2.7%) were among the most common comorbidities by pooled prevalence rates, with the highest certainty of evidence for associations with thyroid disease and alopecia areata. In addition, there was high or moderate certainty of evidence that greater vitiligo extent is associated with increasing prevalence of thyroid disease, type 1 diabetes, rheumatoid arthritis, and pernicious anemia.</p><p><strong>Conclusions: </strong>There is clear evidence of correlations between vitiligo and select autoimmune comorbidities in US adults despite the limitations of this study, including the small number of available high-quality studies. The findings presented here demonstrate the importance of future longitudinal studies to identify causal links between vitiligo and comorbidities, and to evaluate potential benefits of screening and early management for thyroid disease, rheumatoid arthritis, and other autoimmune comorbidities.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence and Association of Autoimmune Comorbidities Among Adults with Vitiligo: A Systematic Literature Review and Meta-analysis of USA-Based Studies.\",\"authors\":\"Jinan Liu, Sudheer Matangi, Yogitha Malempati, Adnan Nasir, David Rosmarin\",\"doi\":\"10.1007/s13555-025-01506-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Vitiligo is an autoimmune, depigmenting skin disease affecting 0.1-1.6% of adults in the USA. Despite observed correlations between vitiligo and other autoimmune conditions in global patient populations, a focused review of comorbidities in US patients with vitiligo is lacking. This systematic literature review and meta-analysis evaluated the prevalence of autoimmune comorbidities in adult patients with vitiligo in the USA.</p><p><strong>Methods: </strong>A systematic literature search of the PubMed and Embase electronic databases (January 1, 2012-November 30, 2022) selected observational studies reporting data on prevalence of autoimmune diseases in US patients with vitiligo. The Grading of Recommendations, Assessment, Development, and Evaluation approach for prognosis was applied to assess certainty of evidence.</p><p><strong>Results: </strong>Eight studies were eligible for inclusion, encompassing 10,246 patients with vitiligo. Thyroid diseases (14.2%), psoriasis (5.1%), rheumatoid arthritis (3.2%), and alopecia areata (2.7%) were among the most common comorbidities by pooled prevalence rates, with the highest certainty of evidence for associations with thyroid disease and alopecia areata. In addition, there was high or moderate certainty of evidence that greater vitiligo extent is associated with increasing prevalence of thyroid disease, type 1 diabetes, rheumatoid arthritis, and pernicious anemia.</p><p><strong>Conclusions: </strong>There is clear evidence of correlations between vitiligo and select autoimmune comorbidities in US adults despite the limitations of this study, including the small number of available high-quality studies. The findings presented here demonstrate the importance of future longitudinal studies to identify causal links between vitiligo and comorbidities, and to evaluate potential benefits of screening and early management for thyroid disease, rheumatoid arthritis, and other autoimmune comorbidities.</p>\",\"PeriodicalId\":11186,\"journal\":{\"name\":\"Dermatology and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13555-025-01506-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01506-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Prevalence and Association of Autoimmune Comorbidities Among Adults with Vitiligo: A Systematic Literature Review and Meta-analysis of USA-Based Studies.
Introduction: Vitiligo is an autoimmune, depigmenting skin disease affecting 0.1-1.6% of adults in the USA. Despite observed correlations between vitiligo and other autoimmune conditions in global patient populations, a focused review of comorbidities in US patients with vitiligo is lacking. This systematic literature review and meta-analysis evaluated the prevalence of autoimmune comorbidities in adult patients with vitiligo in the USA.
Methods: A systematic literature search of the PubMed and Embase electronic databases (January 1, 2012-November 30, 2022) selected observational studies reporting data on prevalence of autoimmune diseases in US patients with vitiligo. The Grading of Recommendations, Assessment, Development, and Evaluation approach for prognosis was applied to assess certainty of evidence.
Results: Eight studies were eligible for inclusion, encompassing 10,246 patients with vitiligo. Thyroid diseases (14.2%), psoriasis (5.1%), rheumatoid arthritis (3.2%), and alopecia areata (2.7%) were among the most common comorbidities by pooled prevalence rates, with the highest certainty of evidence for associations with thyroid disease and alopecia areata. In addition, there was high or moderate certainty of evidence that greater vitiligo extent is associated with increasing prevalence of thyroid disease, type 1 diabetes, rheumatoid arthritis, and pernicious anemia.
Conclusions: There is clear evidence of correlations between vitiligo and select autoimmune comorbidities in US adults despite the limitations of this study, including the small number of available high-quality studies. The findings presented here demonstrate the importance of future longitudinal studies to identify causal links between vitiligo and comorbidities, and to evaluate potential benefits of screening and early management for thyroid disease, rheumatoid arthritis, and other autoimmune comorbidities.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
